rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BIIB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline
      13h agoBenzingaBIIB
      Biogen (BIIB) Posts Positive Two Year Diranersen Results And Five Year Lecanemab Data
      13h agoYahoo FinanceBIIB
      Needham reiterates Biogen stock rating on Alzheimer’s drug data
      15h agoInvesting.comBIIB
      Biogen (BIIB) After Fresh Alzheimer’s Data, Is The Valuation Story Still Compelling?
      15h agoYahoo FinanceBIIB
      Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
      Nov 17Yahoo FinanceBIIB
      Biogen releases new mid-stage data for early Alzheimer's asset diranersen

      Biogen's diranersen Alzheimer's extension showed 38% benefit at week 96, a 1.09-point CDR-SB difference; CELIA missed its 76-week endpoint.

      Nov 17Seeking AlphaBIIB
      Biogen: 3 Key Takeaways for Long-Term Investors
      Nov 17Yahoo FinanceBIIB
      Biogen reports positive two-year data for Alzheimer’s drug
      Nov 17Investing.comBIIB
      Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
      Nov 17ReutersBIIB
      Biogen Inc. stock underperforms Thursday when compared to competitors
      Nov 12MarketWatchBIIB
      Biogen stock hits 52-week high at 258.81 USD
      Nov 9Investing.comBIIB
      Piper Sandler raises Biogen stock price target on pipeline strength
      Nov 9Investing.comBIIB
      Biogen Inc. stock underperforms Thursday when compared to competitors
      Nov 5MarketWatchBIIB
      Biogen’s (BIIB) Pipelines Offers Multiple Potential Catalysts
      Nov 5Yahoo FinanceBIIB
      Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
      Nov 5Yahoo FinanceBIIB
      Is Alzheimer’s Data Altering The Investment Case For Biogen (BIIB)?

      Biogen recently shared new clinical, biomarker and safety data on its Alzheimer’s portfolio at the CTAD 2026 conference, including extended Phase 2 CELIA results for diranersen and long term analyses for lecanemab. The breadth of readouts, from 96 week diranersen extension data to real world lecanemab evidence, highlights how Alzheimer’s programs are shaping Biogen’s future treatment mix and operational focus. We will now look at how Biogen’s investment narrative could be influenced by the...

      Nov 5Yahoo FinanceBIIB
      Guggenheim raises Biogen stock price target to $300 on growth portfolio strength
      Nov 2Investing.comBIIB
      Biogen (BIIB) Receives a Buy from TD Cowen

      Tipranks Press Release.

      Oct 30The Globe and MailBIIB
      Freedom Broker raises Biogen stock price target on strong results
      Oct 29Investing.comBIIB
      Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says

      Biogen (BIIB) has swung back to growth as shown by its solid Q3 results, RBC analysts wrote in a not

      Oct 29Yahoo FinanceBIIB
      Argus upgrades Biogen stock rating on rare disease strength
      Oct 29Investing.comBIIB
      These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
      Oct 29BenzingaBIIB
      Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
      Oct 29Yahoo FinanceBIIB
      BofA raises Biogen stock price target to $257 on solid results
      Oct 29Investing.comBIIB
      Biogen (BIIB) Stock Price Tracks Q3 Results Through Loss And Cash Flow
      Oct 29Yahoo FinanceBIIB
      Biogen Inc (BIIB) (Q3 2026) Earnings Call Highlights: Revenue Climbs 11% as Growth Portfolio ...
      Oct 29Yahoo FinanceBIIB
      Baird raises Biogen stock price target on rare disease strength
      Oct 28Investing.comBIIB
      Biogen Q3 Earnings Call Highlights
      Oct 28Yahoo FinanceBIIB
      Biogen Inc. Q3 2026 Earnings Call Summary
      Oct 28Yahoo FinanceBIIB
      Biogen (BIIB) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Oct 28The Globe and MailBIIB
      BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
      Oct 28Yahoo FinanceBIIB
      Biogen Q3 2026 slides: growth portfolio surpasses legacy MS business
      Oct 28Investing.comBIIB
      Biogen Q3 Earnings Beat Estimates as Revenue Rises 11% and 2026 Profit Guidance Improves
      Oct 28Yahoo FinanceBIIB
      Biogen Q3 2026 Earnings Call Transcript
      Oct 28BenzingaBIIB
      Biogen stock hits 52-week high at $256.00
      Oct 28Investing.comBIIB
      Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
      Oct 28Yahoo FinanceBIIB
      What Biogen Doubters Overlooked
      Oct 28Yahoo FinanceBIIB
      Biogen (NASDAQ:BIIB) delivers impressive Q3 2026
      Oct 28Yahoo FinanceBIIB
      Biogen earnings beat by $0.60, revenue topped estimates
      Oct 28Investing.comBIIB
      Biogen Makes A Solid Return 'To Growth' — What To Know

      Biogen crushed third-quarter expectations early Tuesday, helped by its suite of newer products and leading to a guidance hike.

      Oct 28Investor's Business DailyBIIB
      Biogen Swings to Loss, Logs Higher Sales

      The biotechnology company said the swing to a loss was primarily due to transaction-related charges.

      Oct 28WSJBIIB
      Biogen posts Q3 beat on multiple sclerosis drugs (BIIB:NASDAQ)
      Oct 28Seeking AlphaBIIB
      Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates
      Oct 28Yahoo FinanceBIIB
      Biogen beats Q3 estimates, raises guidance floor on growth
      Oct 28Investing.comBIIB
      Biogen Sales Top Estimates With Help From Newly Acquired Drugs
      Oct 28BloombergBIIB
      Biogen beats third-quarter results on strength in rare disease drugs
      Oct 28ReutersBIIB
      Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack.

      Biogen is leaning on newer drugs, including recently acquired assets, as its multiple sclerosis franchise faces ongoing competition.

      Oct 28Barron'sBIIB
      Biogen set to report earnings as Apellis integration begins
      Oct 27Investing.comBIIB
      Biogen (BIIB) Nears Earnings As Investors Ask If The Stock Is Already Fully Valued
      Oct 27Yahoo FinanceBIIB
      Biogen earnings: what to look for from BIIB
      Oct 27Yahoo FinanceBIIB

      This is the newest page. Registered accounts read further back.